Q1 2023 Results slide image

Q1 2023 Results

Company overview Innovation: Pipeline overview Cardiovascular Financial review Financial performance Immunology Ophthalmology Conclusions Ophthalmology Neuroscience Global Health Appendix References Innovation: Clinical trials Abbreviations Oncology Other Biosimilars 83 Investor Relations | Q1 2023 Results 1 NOVARTIS | Reimagining Medicine
View entire presentation